UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stock Position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 193.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 353,508 shares of the biopharmaceutical company’s stock after purchasing an additional 233,121 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.14% of Lexicon Pharmaceuticals worth $261,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of LXRX. Tang Capital Management LLC grew its position in shares of Lexicon Pharmaceuticals by 750.3% in the 4th quarter. Tang Capital Management LLC now owns 850,268 shares of the biopharmaceutical company’s stock worth $628,000 after buying an additional 750,268 shares during the last quarter. Point72 Asset Management L.P. boosted its holdings in Lexicon Pharmaceuticals by 630.7% in the fourth quarter. Point72 Asset Management L.P. now owns 8,988,421 shares of the biopharmaceutical company’s stock valued at $6,638,000 after acquiring an additional 7,758,371 shares in the last quarter. Deutsche Bank AG increased its position in Lexicon Pharmaceuticals by 378.0% during the 4th quarter. Deutsche Bank AG now owns 315,659 shares of the biopharmaceutical company’s stock valued at $234,000 after purchasing an additional 249,616 shares during the period. Bank of America Corp DE raised its holdings in Lexicon Pharmaceuticals by 27.4% in the 4th quarter. Bank of America Corp DE now owns 136,407 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 29,319 shares in the last quarter. Finally, Bayesian Capital Management LP purchased a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter worth about $31,000. Hedge funds and other institutional investors own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Price Performance

Shares of NASDAQ LXRX opened at $0.70 on Friday. The company has a 50 day simple moving average of $0.63 and a two-hundred day simple moving average of $0.65. Lexicon Pharmaceuticals, Inc. has a fifty-two week low of $0.28 and a fifty-two week high of $2.45. The company has a market capitalization of $251.53 million, a price-to-earnings ratio of -0.93 and a beta of 1.00. The company has a debt-to-equity ratio of 0.56, a quick ratio of 7.43 and a current ratio of 7.45.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings data on Tuesday, May 13th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.03. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. The company had revenue of $1.26 million during the quarter, compared to analyst estimates of $1.26 million. Analysts expect that Lexicon Pharmaceuticals, Inc. will post -0.66 EPS for the current fiscal year.

Analyst Ratings Changes

LXRX has been the topic of several research analyst reports. Wall Street Zen assumed coverage on shares of Lexicon Pharmaceuticals in a research report on Monday, April 21st. They set a “sell” rating on the stock. Piper Sandler decreased their target price on Lexicon Pharmaceuticals from $10.00 to $6.00 and set an “overweight” rating for the company in a research report on Friday, March 7th. Needham & Company LLC restated a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Monday, March 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price target on shares of Lexicon Pharmaceuticals in a research note on Friday, March 28th. Finally, Leerink Partners reissued a “market perform” rating and set a $1.00 price objective (down previously from $2.00) on shares of Lexicon Pharmaceuticals in a research report on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $3.67.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.